Xofluza: payments to doctors
Payments that named Xofluza as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.1M
- Providers
- 35,387
- Transactions
- 71,824
- Average per transaction
- $30
The per-transaction average — $30 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 35,387 providers the average total is $60, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $1,935,913 | 90.7% |
| Genentech, Inc. | $118,301 | 5.5% |
| F. Hoffmann-la Roche AG | $51,430 | 2.4% |
| Shionogi Inc | $14,541 | 0.7% |
| Roche Products Limited | $13,410 | 0.6% |